Table 3.
Patient response, recovery, and remission rates at check-in (primary cohort) and termination (secondary cohort).
| Measures | Clinical check-in (primary cohort) | Termination (secondary cohort) | Early terminators (<4 sessions) | |
|
|
Outcome (95% CI), % | Outcome (95% CI), % | Outcome (95% CI), % | |
| Joint measures | ||||
|
|
Clinically meaningful improvementa | 71.3 (69.7-72.9) | 79.2 (77.5-80.9) | 55.4 (48.7-62.1) |
|
|
Recoveryb | 53.2 (51.4-55.0) | 65.2 (63.2-67.2) | 35.7 (29.2-42.2) |
|
|
Reliable improvementc | 65.8 (64.0-67.5) | 74.8 (73.0-76.6) | 47.4 (40.7-54.2) |
|
|
Remissiond | 16.4 (15.0-17.7) | 27.7 (25.9-29.6) | 5.6 (2.5-8.8) |
|
|
Reliable deterioratione | 7.9 (7.0-8.9) | 6.0 (5.0-7.0) | 10.3 (6.2-14.4) |
| PHQ-9f measures | ||||
|
|
Reliable improvement | 53.0 (51.1-55.0) | 65.3 (63.1-67.5) | 36.6 (29.4-43.8) |
|
|
Responseg | 36.4 (34.5-38.3) | 51.1 (48.8-53.4) | 13.7 (8.6-18.9) |
|
|
Recovery | 55.1 (53.2-57.1) | 66.6 (64.4-68.7) | 35.4 (28.3-42.6) |
|
|
Remission | 19.5 (17.9-21.1) | 32.3 (30.2-34.5) | 6.9 (3.1-10.6) |
|
|
Reliable deterioration | 3.5 (2.8-4.2) | 3.4 (2.6-4.3) | 5.1 (1.8-8.4) |
| GAD-7h measures | ||||
|
|
Reliable improvement | 64.4 (62.4-66.4) | 73.6 (71.5-75.7) | 38.7 (31.1-46.2) |
|
|
Response | 41.1 (39.0-43.1) | 55.8 (53.4-58.1) | 14.7 (9.2-20.2) |
|
|
Recovery | 61.5 (59.4-63.5) | 71.9 (69.7-74.0) | 37.4 (29.9-44.9) |
|
|
Remission | 20.8 (19.1-22.5) | 34.0 (31.8-36.3) | 4.9 (1.6-8.3) |
|
|
Reliable deterioration | 4.7 (3.8-5.6) | 3.9 (3.0-4.8) | 3.7 (0.8-6.6) |
aThe patient met the criteria for joint measures for reliable improvement or recovery.
bAt the clinical end point, both General Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) scores were <10. For individual measures, recovery requires either the PHQ-9 or the GAD-7 score to be <10.
cAt the clinical end point, the patient showed improvement of at least 5 points on the PHQ-9 or 4 points on GAD-7, without a decline of 5 or 4 points on the other measure, respectively. Reliable improvement requires an improvement of at least 5 points for PHQ-9 measures and at least 4 points for GAD-7 measures.
dAt the clinical end point, both GAD-7 and PHQ-9 scores were <5. For individual measures, remission requires either the PHQ-9 or the GAD-7 score to be <5.
eAt the clinical end point, the patient showed an increase of at least 5 points on the PHQ-9 or 4 points on GAD-7. Reliable deterioration requires an increase of at least 5 points for PHQ-9 measures and at least 4 points for GAD-7 measures.
fPHQ-9: Patient Health Questionnaire-9. Patients with PHQ-9 scores≥10 at baseline were included.
gAt the clinical end point, the patient achieved 50% or greater improvement from the baseline score.
hGAD-7: General Anxiety Disorder-7. Patients with GAD-7 scores≥10 at baseline were included.